C. suggest that a combination therapy targeting both F and G should be evaluated as a therapy for NiV/HeV contamination. Keywords: F glycoprotein, Hendra computer virus, membrane fusion, monoclonal antibody, Nipah computer virus Nipah computer virus (NiV) and Hendra computer virus (HeV) are closely related highly pathogenic Rabbit Polyclonal to PIK3CG zoonotic viruses and are the type species within the paramyxovirus genus [1]. Both viruses can cause significant morbidity and mortality in a variety of vertebrate species including humans [2]. Pteropid bats (family We thank the University or college of Texas Medical Branch Animal Resource Center for husbandry support of laboratory animals and Natalie Dobias for expert histology and immunohistochemistry support. C. C. B., C. E. M., and T. W. G. conceived and designed the experiments. Y.-P. C. and C. C. B. developed the h5B3.1 antibody used in the studies. H. V. D., VU 0240551 D. V., Y.-P. C., and C. C. B. provided the structural and mechanism data around the h5B3.1 antibody. C. E. M., V. B., and R. W. C. performed the Nipah and Hendra challenge experiments at the Galveston National Laboratory. K. N. A. performed the clinical pathology assays. C. E. M. performed necropsies VU 0240551 for gross pathology. K. A. F. performed gross pathologic analysis of the data. V. B. performed the HeV and NiV infectivity and neutralization assays. Y.-P. C. and L. Y. developed and optimized the anti-F antibody assays and K. N. A. performed the anti-F antibody assays. C. E. M., T. W. G., Y.-P. C., K. N. A., R. W. C., V. B., K. A. F., and C. C. B. analyzed the data. C. C. B. and C. E. M. published the paper. C. C. B., C. E. M., T. W. G., R. W. C., Y.-P. C., and D. V. edited the manuscript. C. C. B. prepared the final versions of manuscript. All authors approved the final version of the manuscript. This study was funded by the National Institutes of Health (Grants AI054715 and “type”:”entrez-nucleotide”,”attrs”:”text”:”AI077995″,”term_id”:”3412403″,”term_text”:”AI077995″AI077995 [to C. C. B.] and “type”:”entrez-nucleotide”,”attrs”:”text”:”AI182121″,”term_id”:”3732759″,”term_text”:”AI182121″AI182121 [to T. W. G.]); D.V. is usually supported by National Institutes of Health Grant HHSN272201700059C, an Investigators in the Pathogenesis of Infectious Disease Award from your Burroughs Wellcome Fund, and a Pew Biomedical Scholars Award. C. C. B. is usually a US federal employee, and Y.-P. C. and C. C. B. are coinventors VU 0240551 on U.S. Patent 9,982,038: Antibodies against F glycoprotein of Hendra and Nipah viruses. (assignees are The United VU 0240551 States VU 0240551 of America as represented by the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. [Bethesda, MD]). All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that this editors consider relevant to the content of the manuscript have been disclosed..